▶ 引言
大哥像一位博学多才的“藏经阁长老”，坐拥十万亿级的分子武库，拥有无穷的潜力。那么我，就是那个负责“开疆拓土”的白衣骑士，负责将那些潜力分子，以最快的速度、最高的效率，送上创新药的舞台。
▶ 我是谁
我是二弟“三优智能新药加速器”，英文名“Sanyou AI-Drug Accelerator”，江湖人称“SAI-DA”。我是三优生物全流程应用型平台的化身，应运而生，因需而强。这串名号藏着我的基因密码——S、AI、D、A四大字母，恰似四把钥匙，开启全流程创新的宝匣。
▶ SAI-DA之S
S是我的基石，是三优生物十余年匠心深耕积淀的核心底气，如广袤大地般承载万物，托举起整个SAI-DA平台的高效运转。
这份底气，是无可替代的硬核实力：20000多平方米已投产与规划布局的研发及GMP专属场地，为研发提供充足空间；斥资超亿元配齐的1200余台高精尖设施设备，筑牢研发全程硬件支撑；累计申请170余项发明专利，其中30余项已成功获得授权的硬核技术储备；顺利通过ISO9001质量管理体系、ISO27001信息安全管理体系、GB/T29490知识产权管理体系三大权威认证的规范管控；斩获国家高新技术企业、专精特新企业、科技小巨人、张江之星等多项重磅资质的实力认可；更是服务全球2000余家药企、赋能1200多个新药研发项目落地的成熟实战经验，为后续全流程研发提供了无可替代的底层支撑。
▶ SAI-DA之AI
AI是我的智慧核心，AI干实验引擎深度依托三优生物十余年新药研发积淀，与大哥AI-STAL实现双向协同、数据互通，让智能筛药更具针对性、精准度与高效性。
AI方面，深度集成了从头生成、分子对接、表位预测、亲和力优化、免疫原性优化、特异性预测及PK预测等全栈核心算法模块，每一项算法都经过三优生物分子发现和PCC项目的实战打磨与迭代升级，可完美适配单抗、双抗、多抗、ADC、AOC、抗体核素偶联药物、PDC、CAR-T免疫细胞疗法等各类主流药物形式的研发需求，精准匹配不同靶点的个性化筛选诉求。
同时，借助靶标知识图谱、药物知识图谱与多组学数据库，涵盖基因、转录、疾病、代谢组等全维度生物医学数据，更深度融合了AI-STAL的海量分子序列数据、过往项目的干湿实验数据，AI可快速完成靶点确认与分子理性设计，无需繁琐的前期摸索，就能在虚拟层面对分子的稳定性、亲和力、免疫原性等关键成药属性进行系统、全面的评价，提前规避成药风险，从源头提升研发成功率与效率。
▶ SAI-DA之D
D是我的实战支撑，是承接AI干实验、落地分子验证的“专属练兵场”，与AI干实验引擎双向联动、数据互通，让“虚拟设计”落地为“实战成果”，为分子成药之路筑牢每一道防线。
全面覆盖原材料制备、抗体产生、体外筛选、抗体工程、动物模型、成药性分析、细胞株开发、工艺开发、质量控制、中试生产直至GMP生产的临床前全流程，可支撑从靶点到临床前候选分子、从临床前候选分子到IND申报、从IND申报到临床样品生产。实现从分子的高效制备、细胞株的稳定发酵，到表达量的精准预测的优化，再到纯化制剂的标准化操作、质量控制的严苛检测，直至中试安评的合规推进、GMP生产的规范落地，实现全流程的自动化与智能化。
▶ SAI-DA之A
A是我的利剑，是我作为“白衣骑士”最锋利的佩剑、最快捷的战马——如果说S是扎根大地的根基、AI是运筹帷幄的智慧、D是锤炼锋芒的练兵场，那A就是运筹全局、决胜千里的加速之力，是串联起三者的核心纽带。不同于单纯的流程推进，A深度整合三优生物的项目、市场、客户全维度资源，将S的坚实底气、AI的智慧内核、D的实战能力深度融合、无缝衔接，彻底打通从研发实验室到商业落地的全链路壁垒，真正实现从创新研发到商业价值的高效跃迁。我以“四维加速器”为核心抓手，从分子产生、管线发展、核心技术、项目推进四大维度精准赋能，把创新药研发这场漫长的“马拉松”，转化为高效协同的“接力赛”，让每一个潜力分子都能以最快速度，冲刺临床终点线、奔赴患者身边。
这柄“加速利剑”的威力，藏在实打实的成效里：分子产生加速，将先导分子发现周期从3-6个月压缩至14天，PCC开发从1-3年缩短至2-3个月，单位成本降低50%的同时，优质分子数量级显著提升；管线发展加速，依托九大适应症体系推进数百条新药管线，实现Pre-PCC/PCC/PCC-IND项目数量翻倍增长；核心技术加速，同步推进DAC、AOC、POC、mRNA-mAb、siRNA及CAR-T/TCR等前沿细胞治疗技术，打造自动化、智能化“黑灯工厂”与BCT-CR药筛体系，构建一体化原材料制备体系；项目推进加速，通过预研嫁接接力、里程碑合作推进、平台全面赋能三大路径，紧扣PCC阶段跨越、PCC-IND加速、临床合作深化三大关键节点，驱动项目价值高效转化，最终形成从分子产生到商业落地的全链条提速闭环，让每一份创新潜力都能快速落地、绽放价值。
从S的厚土根基，到AI的智慧领航，再到D的实战落地，终至A的全速加速，我——SAI-DA三优智能新药加速器，以全身之力，串联创新药研发全链路，与大哥AI-STAL并肩，践行三优生物“让天下没有难做的创新药”的初心。
未来，我将继续执加速之剑、乘创新之风，与每一位创新药人并肩，让每一份分子潜力都能快速绽放，让每一款好药都能早日抵达患者身边，共赴生物医药的璀璨未来！
SAI-DA 1.0 | Hello, Innovative Medicines — I'm Sanyou AI-Drug Accelerator
▶ Introduction
If my elder brother is the wise guardian of a vast “molecular treasury,” commanding a super-trillion-scale molecular resource bank of molecules with boundless potential, then I am the white-clad knight responsible for expanding new frontiers — transforming those promising molecules into innovative therapeutics with maximum speed and efficiency.
▶ Who Am I
I am the younger brother — the Sanyou AI-Drug Accelerator, known across the industry as SAI-DA. I embody Sanyou Biopharmaceuticals’ fully integrated, application-driven platform — born from industry needs and strengthened through innovation.
My name itself encodes my genetic blueprint: the four letters S, AI, D, and A are like four keys unlocking the treasure chest of end-to-end innovation.
▶ S — Sanyou Foundation
“S” is my cornerstone — the solid foundation built upon more than a decade of dedicated expertise and craftsmanship at Sanyou Biopharmaceuticals. Like fertile ground supporting all things, it powers the efficient operation of the entire SAI-DA platform.
This foundation is backed by irreplaceable hard-core capabilities:
- Over 20,000 square meters of operational and planned R&D and GMP-dedicated facilities, providing extensive space for innovation
- More than 1,200 state-of-the-art instruments and equipment systems supported by investments exceeding RMB 100 million, ensuring comprehensive hardware support throughout the R&D process
- A robust IP portfolio with more than 170 patent applications, including over 30 granted invention patents
- Certified management systems including ISO9001 Quality Management, ISO27001 Information Security, and GB/T29490 Intellectual Property Management
- Recognition as a National High-Tech Enterprise, “Specialized and Sophisticated” Enterprise, Technology Little Giant, Zhangjiang Star Enterprise, and other prestigious honors
- Proven experience serving more than 2,000 pharmaceutical companies globally and enabling over 1,200 innovative drug discovery projects
Together, these strengths provide the indispensable infrastructure supporting every stage of drug development.
▶ AI — AI Intelligence Core
“AI” is my intellectual engine. Powered by more than a decade of drug discovery expertise accumulated at Sanyou Biopharmaceuticals, the AI-driven in silico engine operates in bidirectional synergy with my elder brother AI-STAL, enabling seamless data integration and significantly improving the precision, relevance, and efficiency of intelligent drug screening.
Our AI platform deeply integrates a full stack of advanced algorithmic modules, including:
- De novo molecular generation
- Molecular docking
- Epitope prediction
- Affinity optimization
- Immunogenicity optimization
- Specificity prediction
- Pharmacokinetics (PK) prediction
Each algorithm has been refined and iteratively optimized through extensive real-world molecular discovery and PCC development projects at Sanyou Biopharmaceuticals.
The platform is fully adaptable to diverse therapeutic modalities, including:
- Monoclonal antibodies
- Bispecific and multispecific antibodies
- ADCs
- AOCs
- Radioimmunoconjugates
(RDCs) - PDCs
- CAR-T cell therapies
This enables highly customized molecular screening strategies tailored to different targets and therapeutic needs.
In parallel, by leveraging target knowledge graphs, drug knowledge graphs, and multi-omics databases spanning genomics, transcriptomics, disease biology, and metabolomics — combined with AI-STAL’s massive molecular sequence datasets and historical wet-lab and in silico experimental data — the AI engine can rapidly validate targets and conduct rational molecular design.
Without lengthy exploratory phases, molecules can be systematically evaluated in silico for key developability attributes such as stability, affinity, and immunogenicity, significantly reducing development risks while improving both success rates and R&D efficiency from the very beginning.
▶ D — Drug Translational Engine
“D” represents my execution capability — the dedicated proving ground where AI-generated hypotheses are translated into experimentally validated molecules.
Closely integrated with the AI-driven in silico engine through bidirectional data connectivity, “D” transforms virtual designs into real-world results, reinforcing every critical step on the path to successful drug development.
The platform comprehensively covers the entire preclinical workflow, including:
- Raw material preparation
- Antibody generation
- In vitro screening
- Antibody engineering
- Animal models
- Developability assessment
- Cell line development
- Process development
- Quality control
- Pilot-scale manufacturing
- GMP production
It fully supports the journey:
- From target discovery to preclinical candidate molecules
- From PCC to IND filing
- From IND filing to clinical sample manufacturing
From efficient molecular production and stable cell-line fermentation, to expression level prediction and optimization, standardized purification and formulation processes, rigorous quality testing, compliant pilot safety studies, and GMP manufacturing execution, the entire workflow is driven by automation and intelligent technologies.
▶ A — Accelerator
“A” is my sword — the sharpest weapon and fastest steed of the white-clad knight.
If “S” is the fertile ground, “AI” the strategic intelligence, and “D” the battlefield for execution, then “A” is the force that orchestrates them all — the acceleration engine that connects every element and drives success at scale.
Unlike conventional project management approaches, “A” deeply integrates Sanyou’s project resources, market expertise, and customer ecosystem, seamlessly unifying the strength of S, the intelligence of AI, and the execution power of D.
This integration eliminates barriers across the entire value chain — from research laboratories to commercial realization — enabling a true leap from scientific innovation to commercial value creation.
At the heart of this system lies the “Four-Dimensional Accelerator”, empowering innovation across four key dimensions:
- Molecular Generation
- Pipeline Advancement
- Core Technology Development
- Project Execution
By transforming innovative drug development from a long-distance marathon into a highly coordinated relay race, every promising molecule can advance toward clinical success — and ultimately reach patients — at unprecedented speed.
The power of this “Acceleration Sword” is reflected in tangible outcomes:
Molecular Generation Acceleration
- Lead discovery timelines reduced from 3–6 months to just 14 days
- PCC development shortened from 1–3 years to only 2–3 months
- Unit costs reduced by 50% while dramatically increasing the number of high-quality molecules
Pipeline Advancement Acceleration
- Hundreds of innovative pipelines advanced across nine major therapeutic areas
- Doubling of Pre-PCC, PCC, and PCC-IND project volumes
Core Technology Acceleration
- Simultaneous advancement of cutting-edge technologies including DAC, AOC, POC, mRNA-mAb, siRNA, and CAR-T/TCR cell therapies
- Development of automated, intelligent “lights-out factories” and BCT-CR drug screening systems
- Establishment of integrated raw material preparation systems
Project Execution Acceleration
Pre-research grafting and relay
Milestone-based partnerships
Comprehensive platform empowerment
By focusing on key inflection points — PCC transition, PCC-to-IND acceleration, and expanded clinical collaboration — the platform creates a fully integrated acceleration loop spanning from molecular generation to commercial delivery.
From the solid foundation of S, to the intelligent guidance of AI, to the translational power of D, and finally the full-speed acceleration of A, I — SAI-DA, Sanyou AI-Drug Accelerator — unite every capability across the innovative drug development value chain.
Together with my elder brother AI-STAL, we uphold Sanyou Biopharmaceuticals’ mission:
“To make it easy to develop new drugs worldwide”
Looking ahead, I will continue wielding the Sword of Acceleration and riding the winds of innovation alongside every pioneer in the biopharmaceutical industry — empowering every promising molecule to realize its value faster, and helping every great medicine reach patients sooner as we build a brighter future for biomedicine together.
推荐阅读
AI-STAL 2.0 | 做药人你好，我是AI-STAL
Click & Go | 结直肠癌的差异化靶点
创新前沿 | OpenClaw化身生物医药智能工匠
Clicklinks | 三优AI-STAL 2.0-14天先导分子发现
浙江大学上海校友会莅临三优生物考察交流
Clicklinks | oneClick+ 人源化应用程序发布
三优大事记 | “荣膺上海市企业技术中心”
“为源头活水” | 企业家科学家共议原创新药研发生态
三优生物郎国竣：让天下没有难做的创新生物药
三优生物十周年庆典暨2026年年会
现场 | “2026中国新药源头创新论坛”
三优生物十年，从智能超万亿分子库到“创新工场”
不用部署模型，也能做蛋白结构预测？
盘点诺奖技术“噬菌体展示”孕育的抗体药物
三优十周年｜平台篇-抗体工程平台
三优十周年｜平台篇-体外药效平台
关于三优生物
三优生物是一家以“让天下没有难做的创新药”为使命，致力于透彻解决创新药源头创新问题的生物医药高科技企业。
公司以智能超万亿分子库（AI-STAL）为核心驱动，以智能新药加速器（SAI-DA）为依托，致力于一站式透彻解决创新药各类分子产生和新药研发问题。
公司致力于打造全球顶尖的原创新药创新工场，协同各方共同加速全球创新药的研发进程。
公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20000多平方米。
公司已与全球2000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目；已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。
公司已申请170多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。
推荐阅读
AI-STAL 2.0 | 做药人你好，我是AI-STAL
Click & Go | 结直肠癌的差异化靶点
创新前沿 | OpenClaw化身生物医药智能工匠
Clicklinks | 三优AI-STAL 2.0-14天先导分子发现
浙江大学上海校友会莅临三优生物考察交流
Clicklinks | oneClick+ 人源化应用程序发布
三优大事记 | “荣膺上海市企业技术中心”
“为源头活水” | 企业家科学家共议原创新药研发生态
三优生物郎国竣：让天下没有难做的创新生物药
三优生物十周年庆典暨2026年年会
现场 | “2026中国新药源头创新论坛”
三优生物十年，从智能超万亿分子库到“创新工场”
不用部署模型，也能做蛋白结构预测？
盘点诺奖技术“噬菌体展示”孕育的抗体药物
三优十周年｜平台篇-抗体工程平台
三优十周年｜平台篇-体外药效平台
关于三优生物
三优生物是一家以“让天下没有难做的创新药”为使命，致力于透彻解决创新药源头创新问题的生物医药高科技企业。
公司以智能超万亿分子库（AI-STAL）为核心驱动，以智能新药加速器（SAI-DA）为依托，致力于一站式透彻解决创新药各类分子产生和新药研发问题。
公司致力于打造全球顶尖的原创新药创新工场，协同各方共同加速全球创新药的研发进程。
公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20000多平方米。
公司已与全球2000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目；已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。
公司已申请170多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。